Games developer tinyBuild seeks to boost £500 million market cap by becoming a media company. Watch the full video here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksAvacta Share News (AVCT)

Share Price Information for Avacta (AVCT)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 225.00
Bid: 224.00
Ask: 226.00
Change: 0.00 (0.00%)
Spread: 2.00 (0.89%)
Open: 214.00
High: 234.50
Low: 214.00
Yest. Close: 221.00
AVCT Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

RNS Alerts are a premium feature

Login to your account

myTerminal is a premium feature

Login to your account

Don't have an account? Click here to register.

Avacta confirms efficacy of test on variant Covid-19 strains

Mon, 8th Mar 2021 11:06

(Sharecast News) - Cancer therapies and diagnostics company Avacta announced on Monday that its 'AffiDX' SARS-CoV-2 rapid antigen lateral flow test detected the dominant new variants of coronavirus, known as the B117 or 'Kent', variant, and the D614G variant, as well as the original strain.
The AIM-traded firm said the SARS-CoV-2 virus, like most viruses, mutates over time into slightly different variants.

Some of those variants had been recognised as being more infectious, and thus more rapidly transmissible, with the potential to become dominant strains.

Early on in the pandemic a variant referred to as D614G appeared, which rapidly became the dominant strain globally.

The B117 variant, which was first observed in Kent, was prevalent in the UK, had been found in more than 50 countries and, according to public health and microbiology professor Sharon Peacock at the University of Cambridge, was likely to become the next dominant strain globally.

Avacta said it had carried out analytical tests with the spike proteins isolated from both the B117 and D614G variants, and confirmed that its AffiDX SARS-CoV-2 rapid antigen lateral flow test detected both of those variants, as well as the original strain.

"We are pleased to confirm that Avacta's rapid antigen test detects the B117 strain, an important variant of the SARS-CoV-2 virus and one which is especially prevalent in the UK," said chief executive officer Dr Alastair Smith.

"We have also shown that our test detects the D614G variant, the current dominant global strain.

"We will continue to monitor the performance of the Affimer reagents with future dominant variants as they become available to us."

Dr Smith said that, since the Affimer reagents the company uses in its range of SARS-CoV-2 tests did not bind in the region of the spike protein where the dominant mutations appear, the company did not anticipate that the performance of the tests would be affected.

"Now that we have developed a robust lateral flow test architecture, we can easily insert Affimer reagents that can be very rapidly developed for new variants if necessary, and indeed in response to any other future pandemic virus.

"Our next key milestone is full clinical validation and CE marking of our lateral flow antigen test which we anticipate will be around the end of this quarter and I look forward to updating the market when that milestone is achieved."

At 1048 GMT, shares in Avacta Group were up 7.21% at 213.35p.

More News

Avacta to sell rapid Covid-19 test in EU following registration

(Sharecast News) - Diagnostics and cancer therapies developer Avacta Group has received notice of registration of its 'AffiDX' SARS-CoV-2 antigen lateral flow test in the European Union, allowing it to place the product on the market for professional use in all 27 countries of the EU.

11 Jun 21 12:27

Avacta Covid lateral flow test gets regulatory green light in EU

Avacta Covid lateral flow test gets regulatory green light in EU

11 Jun 21 11:40

IN BRIEF: Avacta Covid lateral flow test gets regulatory green light

IN BRIEF: Avacta Covid lateral flow test gets regulatory green light

7 Jun 21 11:31

Avacta gets MHRA registration for rapid Covid-19 test

(Sharecast News) - Diagnostics and cancer therapy developer Avacta Group announced on Monday that the Medicines and Healthcare products Regulatory Agency (MHRA) has confirmed registration of its 'AffiDX' SARS-CoV-2 antigen lateral flow test for Covid-19, allowing it to place the product on the market in the UK for professional use.

7 Jun 21 10:11

TRADING UPDATES: CML plans AIM move; IronRidge to demerge gold assets

TRADING UPDATES: CML plans AIM move; IronRidge to demerge gold assets

1 Jun 21 20:24

Avacta confident despite filing delay for Covid-19 antigen test

(Sharecast News) - Diagnostics and cancer therapies developer Avacta Group updated the market on its CE-mark submission for its 'AffiDX' SARS-CoV-2 antigen lateral flow test for professional use.

1 Jun 21 11:16

Avacta still waiting on response from UK regulator over Covid test

Avacta still waiting on response from UK regulator over Covid test

28 May 21 11:29

Avacta still waiting on MHRA approval for Covid-19 test

(Sharecast News) - Cancer therapies and diagnostics developer Avacta Group responded to speculation around the CE-mark submission for its SARS-CoV-2 antigen lateral flow test on Friday.

28 May 21 07:29

IN BRIEF: Avacta to sell Covid-19 test in UK in "coming days"

IN BRIEF: Avacta to sell Covid-19 test in UK in "coming days"

10 May 21 11:13

Avacta sees Covid-19 tests driving earnings after reporting 2020 loss

Avacta sees Covid-19 tests driving earnings after reporting 2020 loss

22 Apr 21 12:17

Avacta reports positive data for Covid-19 test product

(Sharecast News) - Diagnostics and cancer therapies developer Avacta announced positive data from the clinical validation of its 'AffiDX' SARS-CoV-2 antigen lateral flow test on Tuesday.

20 Apr 21 15:18

IN BRIEF: Avacta's rapid Covid-19 test is 98% sensitive in trial

IN BRIEF: Avacta's rapid Covid-19 test is 98% sensitive in trial

20 Apr 21 12:17

AIM WINNERS & LOSERS: Warpaint tops outlook; Avacta's Covid test works

AIM WINNERS & LOSERS: Warpaint tops outlook; Avacta's Covid test works

20 Apr 21 11:35

UK earnings, trading statements calendar - next 7 days

UK earnings, trading statements calendar - next 7 days

15 Apr 21 14:56

IN BRIEF: Avacta in global Affimer distribution agreement with Abcam

IN BRIEF: Avacta in global Affimer distribution agreement with Abcam

6 Apr 21 13:53

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.